(Reuters) - The shares of CV Technologies, best known for its COLD-fX
flu and cold treatment, rebounded to close down 25 Canadian
cents, or 16.7 percent, at C$1.25, after falling as low as 85
Canadian cents earlier in the day.
It was the first time the company's stock has traded since
April 19, when regulators slapped a cease trade order on it
following CV's announcement that it planned to voluntarily
restate its year-end results from Sept. 30, 2006, as well as
its results for the following first quarter.
Read more at Reuters.com Government Filings News
flu and cold treatment, rebounded to close down 25 Canadian
cents, or 16.7 percent, at C$1.25, after falling as low as 85
Canadian cents earlier in the day.
It was the first time the company's stock has traded since
April 19, when regulators slapped a cease trade order on it
following CV's announcement that it planned to voluntarily
restate its year-end results from Sept. 30, 2006, as well as
its results for the following first quarter.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment